• 1
    Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 15461554.
  • 2
    Diekema DJ, Beekmann SE, Chapin KC, Morel KA, Munson E, Doern GV. Epidemiology and outcome of nosocomial and community-onset bloodstream infection. J Clin Microbiol 2003; 41: 36553660.
  • 3
    Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165174.
  • 4
    Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159166.
  • 5
    Mulvey MR, Bryce E, Boyd DA et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005; 49: 358365.
  • 6
    Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867878.
  • 7
    Branger C, Zamfir O, Geoffroy S et al. Genetic background of Escherichia coli and extended-spectrum beta-lactamase type. Emerg Infect Dis 2005; 11: 5461.
  • 8
    Mammeri H, Poirel L, Fortineau N, Nordmann P. Naturally occurring extended-spectrum cephalosporinases in Escherichia coli. Antimicrob Agents Chemother 2006; 50: 25732576.
  • 9
    Perez-Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40: 21532162.
  • 10
    Steward CD, Rasheed JK, Hubert SK et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol 2001; 39: 28642872.
  • 11
    Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66: 45554558.
  • 12
    Johnson JR, Clermont O, Menard M, Kuskowski MA, Picard B, Denamur E. Experimental mouse lethality of Escherichia coli isolates, in relation to accessory traits, phylogenetic group, and ecological source. J Infect Dis 2006; 194: 11411150.
  • 13
    Clermont O, Johnson JR, Menard M, Denamur E. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagn Microbiol Infect Dis 2007; 57: 129136.
  • 14
    Clermont O, Lavollay M, Vimont S et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008; 61: 10241028.
  • 15
    Deschamps C, Clermont O, Hipeaux MC, Arlet G, Denamur E, Branger C. Multiple acquisitions of CTX-M plasmids in the rare D2 genotype of Escherichia coli provide evidence for convergent evolution. Microbiology 2009; 155: 16561668.
  • 16
    Clermont O, Dhanji H, Upton M et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64: 274277.
  • 17
    Branger C, Bruneau B, Lesimple AL et al. Epidemiological typing of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates responsible for five outbreaks in a university hospital. J Hosp Infect 1997; 36: 2336.
  • 18
    Canton R, Novais A, Valverde A et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008; 14 (suppl 1): 144153.
  • 19
    Rodriguez-Bano J, Picon E, Gijon P et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 2010; 48: 17261731.
  • 20
    Rodriguez-Bano J, Picon E, Gijon P et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50: 4048.
  • 21
    Brinas L, Lantero M, de Diego I, Alvarez M, Zarazaga M, Torres C. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital. J Antimicrob Chemother 2005; 56: 11071110.
  • 22
    Haldorsen B, Aasnaes B, Dahl KH et al. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 2008; 62: 694702.
  • 23
    Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004). Int J Antimicrob Agents 2006; 28: 578581.
  • 24
    Caroff N, Espaze E, Gautreau D, Richet H, Reynaud A. Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J Antimicrob Chemother 2000; 45: 783788.
  • 25
    Jaurin B, Grundstrom T, Edlund T, Normark S. The E. coli beta-lactamase attenuator mediates growth rate-dependent regulation. Nature 1981; 290: 221225.
  • 26
    Vakulenko SB, Golemi D, Geryk B et al. Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime. Antimicrob Agents Chemother 2002; 46: 19661970.
  • 27
    Mammeri H, Poirel L, Nordmann P. Extension of the hydrolysis spectrum of AmpC beta-lactamase of Escherichia coli due to amino acid insertion in the H-10 helix. J Antimicrob Chemother 2007; 60: 490494.
  • 28
    Mammeri H, Galleni M, Nordmann P. Role of the Ser-287–Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli. Antimicrob Agents Chemother 2009; 53: 323326.
  • 29
    Barnaud G, Benzerara Y, Gravisse J et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother 2004; 48: 10401042.
  • 30
    Boyd DA, Tyler S, Christianson S et al. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob Agents Chemother 2004; 48: 37583764.
  • 31
    Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob Agents Chemother 2009; 53: 28462851.
  • 32
    Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273281.
  • 33
    Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254259.
  • 34
    Corvec S, Prodhomme A, Giraudeau C, Dauvergne S, Reynaud A, Caroff N. Most Escherichia coli strains overproducing chromosomal AmpC beta-lactamase belong to phylogenetic group A. J Antimicrob Chemother 2007; 60: 872876.
  • 35
    Johnson JR, Goullet P, Picard B, Moseley SL, Roberts PL, Stamm WE. Association of carboxylesterase B electrophoretic pattern with presence and expression of urovirulence factor determinants and antimicrobial resistance among strains of Escherichia coli that cause urosepsis. Infect Immun 1991; 59: 23112315.
  • 36
    Johnson JR, van der Schee C, Kuskowski MA, Goessens W, van Belkum A. Phylogenetic background and virulence profiles of fluoroquinolone-resistant clinical Escherichia coli isolates from the Netherlands. J Infect Dis 2002; 186: 18521856.
  • 37
    Oteo J, Delgado-Iribarren A, Vega D et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008; 32: 534537.